ArticleClinical and experimental medicine2026
Opposing prognostic roles of tumor-associated and circulating MMP8 in colorectal cancer.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Local and systemic inflammation play key roles in colorectal cancer (CRC). Matrix metalloproteinase 8 (MMP8), an enzyme involved in extracellular matrix remodeling, has been linked to both inflammatory processes and cancer progression. This study investigates MMP8 serum concentration and MMP8 expression within the tumor microenvironment, and their relationship with tumor characteristics, inflammation, and survival. The study included 776 stage I-IV CRC patients. MMP8+ cell densities within tumors were analyzed using immunohistochemistry combined with digital image analysis, while preoperative serum MMP8 levels were analyzed using an immunofluorometric assay. Survival analyses were performed using the Kaplan-Meier method and Cox regression models. Correlations with systemic inflammatory markers and immune cell densities were assessed using linear regression models. We found that MMP8 was predominantly expressed by CEACAM8+ granulocytes. High MMP8+ cell density within tumors was associated with favorable prognostic factors, including low disease stage, absent lymphovascular invasion, and mismatch repair (MMR) deficiency, but also with improved cancer-specific survival independent of these factors. The multivariable HR for low (vs. high) MMP8+ cell density was 1.76 (95%CI 1.18–2.60). MMP8+ cell density positively correlated with T-cell densities, but not with serum MMP8 levels or conventional systemic inflammation markers. In contrast, high serum MMP8 levels were associated with systemic inflammation and worse survival, but did not remain an independent prognostic factor in multivariable models. In conclusion, serum MMP8 levels do not correlate with MMP8 expression in the tumor microenvironment, suggesting distinct roles for circulating and tumor-associated MMP8 in CRC progression. High MMP8+ cell densities within tumors are associated with better prognosis and local immune activity, while elevated serum MMP8 levels indicate systemic inflammation and advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.